Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bms-852927. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 known ✓ | P55055 | 20/20 | 1.00 |
| ▸ | NR1H3 known ✓ | Q13133 | 18/20 | 1.00 |
| ▸ | RXRA | P19793 | 18/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL780880 | 0.97 | NR1H2 (1.00) | NR1H2RXRANR1H3NR1I2 | |
| SCHEMBL30412305 | 0.96 | NR1H2 (1.00) | NR1H2RXRANR1H3NR1I2 | |
| SCHEMBL779280 | 0.96 | NR1H2 (1.00) | NR1H2RXRANR1H3NR1I2 | |
| SCHEMBL20235389 | 0.94 | NR1H2 (0.89) | NR1H2RXRANR1H3NR1I2 | |
| SCHEMBL16407949 | 0.94 | NR1H2 (0.89) | NR1H2RXRANR1H3NR1I2 | |
| SCHEMBL19579159 | 0.93 | NR1H2 (0.94) | NR1H2RXRANR1H3NR1I2 | |
| SCHEMBL779981 | 0.91 | NR1H2 (0.90) | NR1H2RXRANR1H3NR1I2 | |
| SCHEMBL16407948 | 0.91 | NR1H2 (0.89) | NR1H2RXRANR1H3NR1I2 | |
| SCHEMBL779541 | 0.91 | NR1H2 (1.00) | NR1H2RXRANR1H3NR1I2 | |
| SCHEMBL779391 | 0.91 | RXRA (1.00) | NR1H2RXRANR1H3NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230087388-A1 | INHIBITORS OF HUMAN DEUBIQUITINASES FOR THE TREATMENT OF CORONAVIRAL INFECTIONS | IMMUNOLOGIK GMBH (DE) | 2023-03-23 | — | — | US | claimed |
| EP-4110393-A1 | INHIBITORS OF HUMAN DEUBIQUITINASES FOR THE TREATMENT OF CORONAVIRAL INFECTIONS | Immunologik GmbH (DE) | 2023-01-04 | — | — | EP | claimed |
| CN-115427076-A | Human deubiquitinase inhibitors for the treatment of coronavirus infections | 免疫学有限公司 | 2022-12-02 | — | — | CN | claimed |
| EP-3999055-A1 | METHODS FOR TREATING MEIBOMIAN GLAND DYSFUNCTION WITH LIVER X RECEPTOR AGONISTS | Novartis AG (CH) | 2022-05-25 | — | — | EP | claimed |
| CN-114126618-A | Method of treating meibomian gland dysfunction with liver X receptor agonists | 诺华股份有限公司 | 2022-03-01 | — | — | CN | claimed |
| EP-2435410-B1 | LXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2017-01-18 | — | — | EP | claimed |
| US-8618154-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-12-31 | — | — | US | claimed |
| US-20120071534-A1 | LXR MODULATORS | EXELIXIS, INC. | 2012-03-22 | — | — | US | claimed |
| US-12502368-B2 | Treatment and diagnosis of melanoma | THE ROCKEFELLER UNIVERSITY (US) | 2025-12-23 | — | — | US | disclosed |
| WO-2025059405-A1 | COMPOSITIONS FOR USE IN A METHOD OF TREATING A MOTOR NEURON DISEASE OR CONDITION ASSOCIATED WITH A SPG11 PATHOGENIC VARIANT | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-115427076-B | Human deubiquitinase inhibitors for the treatment of coronavirus infections | 免疫学有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20240293401-A1 | COMBINATION THERAPY WITH AN LXR AGONIST AND AN INHIBITOR COMPOUND | Asteroid Therapeutics (US) | 2024-09-05 | — | — | US | disclosed |
| US-20240252458-A1 | TREATMENT AND DIAGNOSIS OF MELANOMA | THE ROCKEFELLER UNIVERSITY | 2024-08-01 | — | — | US | disclosed |
| CN-116077492-B | Application of glucagon receptor antagonist-3 in preparation of medicine for resisting gram positive bacterial infection | 华中科技大学协和深圳医院 | 2024-03-15 | — | — | CN | disclosed |
| EP-2435410-A2 | LXR MODULATORS | Exelixis Patent Company LLC (US) | 2012-04-04 | — | — | EP | disclosed |
| US-20120071534-A1 | LXR MODULATORS | EXELIXIS, INC. | 2012-03-22 | — | — | US | disclosed |
| US-20120071534-A1 | LXR MODULATORS | EXELIXIS, INC. | 2012-03-22 | — | — | US | disclosed |
| US-20120071534-A1 | LXR MODULATORS | EXELIXIS, INC. | 2012-03-22 | — | — | US | disclosed |
| WO-2010138598-A2 | LXR MODULATORS | EXELIXIS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138598-A2 | LXR MODULATORS | EXELIXIS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252458-A1 | TREATMENT AND DIAGNOSIS OF MELANOMA | EYA3, BRAF, CD99 | NR1H2 4537/4885NR1H3 4400/4885RXRA 2268/4885 |
| US-12502368-B2 | Treatment and diagnosis of melanoma | EYA3, BRAF, CD99 | NR1H2 4537/4885NR1H3 4400/4885RXRA 2268/4885 |
| US-20120071534-A1 | LXR MODULATORS | NR1H3, NR1H2, NR1H4 | NR1H2 2/4885NR1H3 1/4885RXRA 10/4885 |
| US-20230087388-A1 | INHIBITORS OF HUMAN DEUBIQUITINASES FOR THE TREATMENT OF CORONAVIRAL INFECTIONS | USP47, USP7, USP1 | NR1H2 3376/4885NR1H3 3130/4885RXRA 3836/4885 |
| US-20240293401-A1 | COMBINATION THERAPY WITH AN LXR AGONIST AND AN INHIBITOR COMPOUND | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885NR1H3 2/4885RXRA 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.